Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2018

View Archived Issues

FDA removes clinical hold and allows initiation of phase I/II study of MRT-5005

Deinove to acquire Biovertis and clinical-stage antibiotic

Eisai enters research agreement to develop new treatments for tuberculosis

FDA grants fast track designation to tenalisib for the treatment of relapsed/refractory CTCL

Aeglea reports phase I/II data on pegzilarginase in patients with arginase 1 deficiency

First patient dosed in first-in-human trial of MSB-2311 in advanced solid tumors

First-in-human data presented for inflammasome modulator SGM-1019

Gilead's presatovir does not improve outcomes in respiratory syncytial virus infection trial

CFDA approves IND for Suzhou Alphamab's HER2 bispecific antibody KN-026

Bristol-Myers Squibb and Illumina collaborate on companion diagnostics for oncology immunotherapies

Herantis reports interim safety data from phase I study of Lymfactin

Bayer initiates phase I study of BAY-2328065 in healthy volunteers

Rimo studies RiMO-301 with radiation in advanced tumors

Pfizer presents data on ACC inhibitor PF-05221304

Eusol initiates phase III study of ES-135 in patients with spinal cord injury

First phase I data reported for heptatis B virus candidate RO-7049389

Bayer presents adenosine A2B receptor antagonists and IL-6 release inhibitors

DGMIF identifies novel WEE1hu inhibitors

Telix establishes research partnership to study use of its clinical targeting agents with astatine

Gilead divulges new PI3K inhibitors

Chugai Pharmaceutical presents new GLP-1 receptor agonists

Shire agrees to sell oncology business to Servier

Tiziana in license agreement with BWH for neurodegenerative diseases

New P2Y6 receptor agonists presented by Tufts University

Stem-cell based regenerative treatment for Alzheimer's administered to first patients in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...